INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of AstraZeneca PLC- AZN
GlobeNewsWire
公開日時: Jul 14, 2026, 08:54 PM
Sentiment Analysis
Pomerantz LLP is investigating claims on behalf of investors of AstraZeneca PLC (“AstraZeneca” or the “Company”) (NYSE: AZN).
Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
The investigation concerns whether AstraZeneca and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
On July 9, 2026, AstraZeneca disclosed that the late-stage Phase-3 CARDIO-TTransform trial of Wainua, an amyloid cardiomyopathy treatment developed in collaboration with Ionis Pharmaceuticals, did not meet its primary endpoint.
On this news, AstraZeneca’s American Depositary Share (“ADS”) price fell $10.79 per ADS, or 5.7%, to close at $187.49 per ADS on July 9, 2026.
Source: GlobeNewsWire
個別の投資に関する推奨やアドバイスを提供することを意図しておりません。ここで述べられている意見や見解は、あくまでも各記事の個人的見解です。